Across the environment, health care personnel and superior-threat teams are beginning to receive COVID-19 vaccines, providing hope for a return to normalcy amidst the pandemic. Even so, the vaccines approved for unexpected emergency use in the U.S. have to have two doses to be powerful, which can generate issues with logistics and compliance. Now, scientists reporting in ACS Central Science have developed a nanoparticle vaccine that elicits a virus-neutralizing antibody reaction in mice just after only a one dose.
The key target for COVID-19 vaccines is the spike protein, which is necessary for SARS-CoV-2’s entry into cells. Equally of the vaccines at this time approved in the U.S. are mRNA vaccines that lead to human cells to temporarily deliver the spike protein, triggering an immune reaction and antibody manufacturing. Peter Kim and colleagues needed to try a different technique: a vaccine consisting of multiple copies of the spike protein shown